Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT

Institutional investor lowers position in biotechnology company

Mar. 16, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an institutional investor, lowered its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 26.4% during the 3rd quarter, according to a recent SEC filing. The investor now owns 645,621 shares of the biotechnology company's stock, down from 877,200 shares previously.

Why it matters

This filing provides insight into the investment decisions of Bamco Inc. NY, a notable institutional investor in the biotechnology sector. Changes in major shareholders' positions can signal shifts in market sentiment or confidence around a company's prospects.

The details

According to the SEC filing, Bamco Inc. NY sold 231,579 shares of Veracyte, Inc. during the 3rd quarter. The institutional investor now owns 645,621 shares, or 0.82% of the biotechnology company's outstanding stock, valued at $22,164,000 as of the most recent filing.

  • The filing covers Bamco Inc. NY's position changes during the 3rd quarter of the year.

The players

Bamco Inc. NY

An institutional investor and asset management firm.

Veracyte, Inc.

A biotechnology company focused on developing and commercializing genomic tests to improve diagnostic accuracy and patient care.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the shifting investment landscape in the biotechnology sector, as major institutional investors adjust their positions based on their assessment of a company's prospects and market conditions.